68Ga-pentixafor PET/CT在BTKi治疗的WM/LPL中与M蛋白疗效标准不一致
该研究为前瞻性队列的事后分析,纳入33例新诊断或复发WM/LPL患者,比较68Ga-pentixafor PET/CT与基于M蛋白的IWWM标准评估疗效。化疗免疫组15例中14例(93.3%)两种评估一致,BTKi组18例中10例(55.6%)不一致;半定量分析显示化疗组PET参数与临床缓解及ΔM-pro%、ΔIgM%强相关,BTKi组无统计学显著相关。
要点
- 化疗免疫组PET/CT与IWWM标准一致率高(14/15,93.3%)
- BTKi组PET/CT与IWWM标准不一致达10/18(55.6%)
- BTKi组PET半定量参数与M蛋白变化无统计学显著相关
核心结论
- 68Ga-pentixafor PET/CT对接受化疗免疫治疗的WM/LPL患者可提供准确的疗效评估。
- BTKi治疗的WM/LPL患者中,68Ga-pentixafor PET/CT疗效与基于M蛋白的IWWM标准不一致,提示IWWM标准在BTKi治疗人群中可能不足。
研究设计与样本
- 本研究为前瞻性队列研究的事后分析,共纳入33例新诊断或复发WM/LPL患者。
- 15例接受化疗免疫治疗(chemo组),18例接受含BTKi方案治疗(BTKi组)。
- 临床疗效采用基于单克隆蛋白水平变化的IWWM标准评估,PET/CT疗效采用视觉和半定量评估。
- 半定量指标包括TLU、MTV和SUVmax,并计算从基线到随访扫描的百分比变化(ΔTLU%、ΔMTV%、ΔSUVmax%),同时计算ΔM-pro%和ΔIgM%。
主要发现
- 视觉评估中,chemo组14/15(93.3%)患者PET/CT与M蛋白-based IWWM标准评估一致。
- BTKi组10/18(55.6%)患者PET/CT-based疗效与IWWM疗效不一致。
- 半定量分析中,chemo组ΔTLU%、ΔMTV%、ΔSUVmax%与临床缓解、ΔM-pro%、ΔIgM%呈强相关(r=0.634-0.856,P<0.05)。
- BTKi组中M蛋白百分比或IgM百分比变化与68Ga-pentixafor PET/CT摄取值之间无统计学显著相关(P>0.05)。
关键数值与推荐
- 临床疗效评估采用基于单克隆蛋白水平变化的IWWM疗效标准。
- PET/CT疗效采用视觉和半定量评估,半定量指标为TLU、MTV、SUVmax及其从基线到随访的百分比变化。
- chemo组PET半定量变化与临床缓解及ΔM-pro%、ΔIgM%的相关系数r=0.634-0.856(P<0.05)。
- BTKi组M蛋白或IgM百分比变化与PET摄取值无统计学显著相关(P>0.05)。
临床怎么用
- 对接受化疗免疫治疗的WM/LPL患者,可用68Ga-pentixafor PET/CT辅助疗效评估。
- 对接受BTKi治疗的WM/LPL患者,解读68Ga-pentixafor PET/CT疗效时需注意其与基于M蛋白的IWWM标准可能不一致。
- BTKi治疗人群中单纯依赖M蛋白-based IWWM标准评估疗效可能存在不足,需结合影像学评估。
局限性
- 本研究为单中心前瞻性队列的事后分析,样本量较小(共33例)。
- BTKi组与chemo组样本量分别为18例和15例,组间比较的统计效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) is a rare, indolent non-Hodgkin lymphoma. Bruton tyrosine kinase inhibitors (BTKis) have been widely used for the treatment of WM/LPL. The objective of this study is to evaluate the response assessed by 68 Ga-pentixafor PET/CT in patients with WM/LPL treated with either BTKi or chemoimmunotherapy. PATIENTS AND METHODS: This is a post hoc analysis of the data from our prospective cohort study. A total of 33 patients with newly diagnosed or relapsed WM/LPL were included. The clinical response was assessed using the International Workshop of WM (IWWM) response criteria based on the change of monoclonal protein level. 68 Ga-pentixafor PET/CT response was evaluated both visually and semiquantitatively. The total lesion uptake (TLU), metabolic tumor volume (MTV), and SUVmax were measured for semiquantitative assessments and were calculated as percentage change from baseline to follow-up scans (∆TLU%, ∆MTV%, ∆SUVmax%). The change of M-protein (∆M-pro%) and IgM (∆IgM%) was also calculated. RESULTS: Among the included patients, 15 received chemoimmunotherapy (chemo-group), while 18 patients were treated with BTKi-containing regimens (BTKi group). In PET/CT visual assessment, 14/15 (93.3%) patients in chemo-group exhibited consistent response, as assessed by 68 Ga-pentixafor PET/CT and M-protein-based IWWM criteria. However, the PET/CT-based response was inconsistent with the IWWM response in 10/18 (55.6%) patients in the BTKi group. For semiquantitative analysis, ∆TLU%, ∆MTV%, and ∆SUVmax% in chemo-group showed a strong correlation with clinical response, ∆M-pro%, and ∆IgM% values (r = 0.634-0.856, P < 0.05). However, there was no statistically significant correlation between the changes in M-protein percentage or IgM percentage and the uptake values measured by 68 Ga-pentixafor PET/CT in BTKi group ( P > 0.05). CONCLUSIONS: 68 Ga-pentixafor PET/CT provides accurate response assessment in WM/LPL patients receiving chemoimmunotherapy. However, the 68 Ga-pentixafor PET/CT-based response exhibited inconsistency with the M-protein-based IWWM criteria in those treated with BTKis, thereby suggesting the potential inadequacy of the IWWM response criteria in WM/LPL patients treated with BTKis.
引用
- Pan Q, Liu S, Zhang H, et al. 68 Ga-pentixafor PET/CT Indicates Inconsistent Response With Monoclonal Protein-based Response Criteria in Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Patients Treated With Bruton Tyrosine Kinase Inhibitors. Clin Nucl Med. 2026. PMID: 42113823. doi:10.1097/RLU.0000000000006518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。